

EXPRESS MAILING LABEL NO. EV104962585US

Attorney Docket No. P51160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10

Applicant: Erskine, et al.

Serial No.: 09/912,483

Group Art Unit No.: 1614

Filed: July 25, 2001

Examiner: James H. Reamer

For: COMPOUNDS AND METHODS FOR THE TREATMENT OF
NEOPLASTIC DISEASE

Commissioner for Patents,
P.O. Box 1450,
Alexandria, VA 22313-1450

RECEIVED

JUN 17 2003

OFFICE OF PETITIONS

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(d),
Petition for Consideration under 37 C.F.R. §1.97(d), and
Certification under 37 C.F.R. §1.97(e)(1) or (e)(2) with Fee,

Information Disclosure Statement. PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed. This statement is being filed under the provisions of 37 C.F.R. §1.97(d) with the required Certification.

Petition to Consider. Applicants petition the Office to consider the Information Disclosure Statement attached hereto in rendering its opinion on the patentability of the subject matter now claimed in the captioned application. The Office is authorized to charge the \$180.00 fee set forth in 37 C.F.R. §1.17(e) against Deposit Account No. 19-2570.


Statement of Certification. The undersigned hereby certifies that each item set out in the attached Form 1449 was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the

Serial No.: 09/912,483
Group Art Unit No.: 1614

filing of this statement, or that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned on reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this Statement.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Andrea V. Lockenour
Attorney for Applicants
Registration No. 51,962

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7568
Facsimile (610) 270-5090

RECEIVED
JUN 17 2003
OFFICE OF PETITIONS